Elan sells Athena Diagnostics to investment firm
This article was originally published in Clinica
Executive Summary
Troubled Irish pharmaceuticals group Elan has sold its Athena Diagnostics business to private equity investment firm Behrman Capital. New York-based Behrman has purchased Elan's 80% stake as well as the remaining stock from minority holders for $122m in total.